Pharmaceutical Technology

OCTOBER 5, 2023

IMIDomics and WuXi Biologics have signed an agreement to advance the development and manufacturing of the humanised antibody, IMB1001

Antibody 130

Antibody Development Manufacturing 130

Pharmaceutical Technology

SEPTEMBER 14, 2023

AbCellera and Incyte have entered a partnership for the discovery and development of therapeutic antibodies in oncology.

Antibody 147

Antibody Development 147

Pharmaceutical Technology

SEPTEMBER 28, 2023

Ono Pharmaceutical and Adimab have signed a drug discovery collaboration agreement for the development of antibody drugs in oncology

Antibody 130

Antibody Development Drugs 130

Pharmaceutical Technology

JULY 3, 2023

Chime Biologics, Leads Biolabs and BeiGene have entered a strategic partnership to expedite the development of a monoclonal antibody, LBL-007.

Antibody 130

Antibody Development 130

Pharmaceutical Technology

SEPTEMBER 1, 2023

Twist and Ono will discover and develop novel antibodies to treat autoimmune diseases and generate comprehensive discovery campaigns.

Antibody 130

Antibody Development 130

Drug Discovery World

APRIL 22, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Development Gene Therapy Marketing 52

Pharmaceutical Technology

JULY 12, 2023

Crossbow Therapeutics has raised Series A funds worth $80m to develop a new class of antibody treatments for cancer.

Antibody 130

Antibody Development 130

Pharmaceutical Technology

SEPTEMBER 22, 2022

Abpro has entered a strategic collaboration with Celltrion for the global development and commercialisation of the former's antibody therapy, a t-cell engager known as ABP 102. The cancer molecule will be developed for treating patients with HER2+ cancer, including gastric, pancreatic and breast cancer.

Antibody 130

Antibody Development Bioinformatics In-Vitro 130

Pharmaceutical Technology

AUGUST 29, 2022

Sanyou Biopharmaceuticals and Shanghai KangaBio have signed a licencing agreement to expedite the development and innovation of the former’s monoclonal antibody drug. Sanyou and KangaBio will join forces to offer new prodrug development for immunotherapy based on their expertise and industry resources.

Antibody 130

Antibody Development Drugs Production 130

Pharmaceutical Technology

MARCH 16, 2023

Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio. The MPN Technology provides an elegant way for delivering antibodies inside tumour cells.

Antibody 262

Antibody In-Vivo Pharma Companies Protein 262

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). As per the terms of the agreement, LegoChem will receive up to $1.25bn in upfront, development and commercial milestone payments from Amgen.

Antibody 130

Antibody Development Drugs Licensing 130

Pharmaceutical Technology

OCTOBER 12, 2022

Biotech start-up Toregem BioPharma has signed a memorandum of understanding (MoU) with WuXi Biologics to develop the monoclonal antibody, TRG035. Under the MoU, the companies will form a collaboration for the development of TRG035, which targets USAG-1 to treat congenital adentia.

Antibody 130

Antibody Development Bioassay Manufacturing 130

Pharmaceutical Technology

OCTOBER 20, 2023

The company plans to initiate the Phase II trial of anti-IL-6 antibody in atherosclerotic cardiovascular disease in 2024.

Antibody 147

Antibody Development Trials 147

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology: Leading companies in cancer monoclonal antibody therapy. Immatics is one of the most important players concerning innovation surrounding cancer monoclonal antibody therapy.

Antibody 261

Antibody Immune Response Protein Development 261

Pharmaceutical Technology

NOVEMBER 16, 2022

Clinical-stage biopharmaceutical companies NextCure and LegoChem Biosciences have signed a collaboration and co-development agreement to develop a B7-H4 antibody drug conjugate (ADC), and features options for two further targets. Furthermore, NextCure signed a supply agreement for Keytruda with Merck.

Antibody 130

Antibody Development Drugs Production 130

Pharmaceutical Technology

FEBRUARY 15, 2024

Ono Pharmaceutical has entered an agreement with Numab Therapeutics for developing and commercialising NM49 in the oncology field.

Development 130

Development Antibody 130

Pharmaceutical Technology

DECEMBER 15, 2023

Teva Pharmaceutical has signed a licence agreement with Biolojic Design for the development of BD9 to treat atopic dermatitis and asthma.

Development 130

Development Antibody 130

Pharmaceutical Technology

FEBRUARY 22, 2024

Ono Pharmaceutical has partnered with EME to advance the drug discovery of VHH antibodies to develop new therapeutic agents.

Antibody 130

Antibody Drugs Development 130

Pharmaceutical Technology

OCTOBER 21, 2022

AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

Antibody 217

Antibody Protein Licensing Licensing 217

Pharmaceutical Technology

JANUARY 23, 2024

Calluna has four monoclonal antibody candidates in the pipeline under development for inflammatory and fibrotic diseases.

Antibody 130

Antibody Development 130

Pharmaceutical Technology

DECEMBER 4, 2023

The $247m deal will focus on the use of generative artificial intelligence to develop an antibody therapy for an unnamed cancer.

Antibody 162

Antibody Drugs Development 162

Pharmaceutical Technology

APRIL 5, 2024

Caris Life Sciences has entered a collaboration with Merck KGaA for the development of antibody-drug conjugates (ADCs) for cancer.

Development 130

Development Life Science Antibody Drugs 130

Pharmaceutical Technology

OCTOBER 26, 2023

The Series A funds will go towards the clinical development of TRIV-509, with plans for a proof-of-concept atopic dermatitis study.

Clinical Development 147

Clinical Development Development Antibody 147

Pharmaceutical Technology

SEPTEMBER 6, 2023

Zenas BioPharma and BMS have signed an agreement for the development and commercialisation of obexelimab to treat autoimmune ailments.

Development 130

Development Antibody 130

Drug Discovery World

MAY 1, 2024

DDW’s Megan Thomas speaks to industry experts and thought leaders about the potential for therapeutic antibodies in 2024. Many of the best-selling drugs in 2023 were monoclonal antibody (mAB) therapies, including Keytruda (pembrolizumab), Humira (adalimumab), and Dupixent (dupilumab) 1.

Antibody 59

Antibody FDA Approval Drugs Development 59

Pharmaceutical Technology

DECEMBER 21, 2023

The FDA released an updated guidance for developing Covid-19 monoclonal antibody treatments for EUAs as variants evolve.

Antibody 130

Antibody Development 130

Pharmaceutical Technology

NOVEMBER 22, 2023

Myricx Bio has signed a licence agreement for contract research, development and manufacturing organisation WuXi Biologics’ antibody.

Antibody 130

Antibody Manufacturing Development Research 130

Pharmaceutical Technology

JULY 21, 2022

AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In May, the company supplied the first doses of the antibody therapy to Swiss hospitals for Covid-19 prevention.

Antibody 264

Antibody Compliance Clinical Trials Clinical Trials 264

Pharmaceutical Technology

MAY 24, 2023

HBM’s wholly owned subsidiary Nona Biosciences has entered an agreement with OPKO Health’s ModeX Therapeutics for the discovery of antibodies. ModeX Therapeutics will gain access to the fully human Harbour Mice platforms of Nona Bioscience for integration into its MSTAR platform to expedite the monoclonal antibodies’ discovery.

Antibody 147

Antibody Clinical Development Development Research 147

Bio Pharma Dive

APRIL 3, 2024

The startup claims to have a more efficient way to develop biologic drugs that treat disease by turning on cellular pathways, rather than blocking them.

Antibody 286

Antibody Drugs Development 286

Pharmaceutical Technology

DECEMBER 18, 2023

Biocytogen Pharmaceuticals and Ona Therapeutics signed an antibody agreement to develop antibody-drug conjugates for solid tumours.

Development 130

Development Antibody Drugs 130

Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.

Antibody 279

Antibody Genotype Licensing Licensing 279

Drug Discovery World

MAY 7, 2024

Dr O’Donnell-Tormey will address the opportunities, innovations and challenges in the therapeutic antibody space. What effect has antibody engineering had on drug discovery and development? The post Where is the opportunity in the therapeutic antibody market? Watch the webinar on-demand now!

Antibody 52

Antibody Marketing Gene Therapy Engineer 52

Bio Pharma Dive

APRIL 19, 2021

Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests.

Antibody 335

Antibody Drugs Development 335

Pharmaceutical Technology

JULY 6, 2023

F-star Therapeutics and Takeda have signed a strategic discovery partnership and licence deal to develop multi-specific immunotherapies.

Development 130

Development Antibody 130

Drug Discovery World

SEPTEMBER 6, 2023

The development of antibodies and associated technologies continues to drive high-value deals, according to a recent report in Nature. In 2022, there were 156 antibody-focused deals with a value of $57.3 billion, up 40% from 2021.

Antibody 52

Antibody Development Sales Manufacturing 52

Pharmaceutical Technology

JANUARY 9, 2023

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.

FDA Approval 246

FDA Approval Antibody Clinical Trials Clinical Trials 246